Research Analysts Issue Forecasts for AnaptysBio Q1 Earnings

AnaptysBio, Inc. (NASDAQ:ANAB) – Research analysts at HC Wainwright cut their Q1 2026 EPS estimates for AnaptysBio in a note issued to investors on Wednesday, March 4th. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will post earnings of ($1.12) per share for the quarter, down from their prior forecast of ($1.02). HC Wainwright currently has a “Buy” rating and a $66.00 target price on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share. HC Wainwright also issued estimates for AnaptysBio’s Q2 2026 earnings at ($1.22) EPS, Q3 2026 earnings at ($1.51) EPS, Q4 2026 earnings at ($1.88) EPS, FY2026 earnings at ($6.52) EPS, FY2027 earnings at ($8.55) EPS, FY2028 earnings at ($3.51) EPS and FY2029 earnings at ($0.61) EPS.

Other analysts have also recently issued research reports about the company. Guggenheim restated a “buy” rating on shares of AnaptysBio in a report on Thursday, December 18th. Stifel Nicolaus upped their price target on shares of AnaptysBio from $56.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday. Wall Street Zen lowered shares of AnaptysBio from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Barclays increased their target price on AnaptysBio from $78.00 to $79.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, UBS Group started coverage on AnaptysBio in a research note on Wednesday, January 7th. They set a “buy” rating and a $70.00 price target for the company. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $73.44.

AnaptysBio Stock Down 3.3%

Shares of NASDAQ:ANAB opened at $55.41 on Friday. The company has a market cap of $1.59 billion, a P/E ratio of -106.56 and a beta of 0.32. The business has a fifty day simple moving average of $50.27 and a 200-day simple moving average of $39.03. AnaptysBio has a 52 week low of $15.32 and a 52 week high of $63.47.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Monday, March 9th. The biotechnology company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.89 by $0.69. The firm had revenue of $108.25 million for the quarter, compared to analyst estimates of $87.09 million. AnaptysBio had a negative net margin of 5.64% and a negative return on equity of 1,101.24%.

Institutional Investors Weigh In On AnaptysBio

Institutional investors and hedge funds have recently modified their holdings of the stock. Smartleaf Asset Management LLC lifted its position in AnaptysBio by 5,864.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 821 shares in the last quarter. Larson Financial Group LLC raised its stake in shares of AnaptysBio by 54.6% during the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 473 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of AnaptysBio by 24.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 263 shares during the period. Bessemer Group Inc. lifted its position in shares of AnaptysBio by 950.0% during the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 1,292 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its position in shares of AnaptysBio by 940.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 1,383 shares in the last quarter.

Insider Buying and Selling

In related news, insider Paul F. Lizzul sold 3,650 shares of the company’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $44.71, for a total transaction of $163,191.50. Following the completion of the sale, the insider directly owned 42,088 shares of the company’s stock, valued at approximately $1,881,754.48. This represents a 7.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric J. Loumeau sold 10,000 shares of the stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $54.00, for a total value of $540,000.00. Following the completion of the sale, the insider owned 12,835 shares of the company’s stock, valued at approximately $693,090. This represents a 43.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 156,280 shares of company stock valued at $7,254,939. 33.50% of the stock is owned by corporate insiders.

AnaptysBio announced that its board has authorized a share buyback plan on Friday, November 21st that permits the company to buyback $100.00 million in shares. This buyback authorization permits the biotechnology company to repurchase up to 9.6% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s management believes its shares are undervalued.

Key AnaptysBio News

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Stifel Nicolaus raised its price target sharply to $85 and kept a buy rating — a sizable upside vs. recent levels that likely boosted investor demand. Stifel raises PT to $85
• Positive Sentiment: Coverage noting a profitability turnaround and continued progress collecting Jemperli royalties supports a higher valuation narrative for ANAB. This fundamental story likely underpins recent buying interest. Assessing AnaptysBio valuation after profitability turnaround
• Positive Sentiment: ANAB hit a new 12‑month high following analyst upgrades, which can attract momentum and technical buying. ANAB hits new 12‑month high on analyst upgrade
• Negative Sentiment: HC Wainwright issued a mixed set of estimate changes: it lowered near‑term FY2026 and Q1/Q2 EPS forecasts (worse near‑term profitability) even as it raised several multi‑year estimates; the negative near‑term revisions could pressure sentiment despite the firm’s buy rating and $66 target. HC Wainwright estimate changes (MarketBeat summary)
• Neutral Sentiment: Short‑interest entries in recent reports are inconsistent/zero (showing NaN increases), indicating unreliable short‑interest data — not a clear driver of today’s move. (No reliable link provided in the filings.)

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.